CSIMarket
 
Virpax Pharmaceuticals Inc   (VRPX)
Other Ticker:  
 
 
Price: $4.1690 $0.30 7.726%
Day's High: $4.1999 Week Perf: -15.78 %
Day's Low: $ 3.40 30 Day Perf: 12.86 %
Volume (M): 16 52 Wk High: $ 11.77
Volume (M$): $ 65 52 Wk Avg: $6.83
Open: $3.79 52 Wk Low: $2.40



 Market Capitalization (Millions $) 49
 Shares Outstanding (Millions) 12
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Virpax Pharmaceuticals Inc
Virpax Pharmaceuticals Inc is a pharmaceutical company that focuses on developing and commercializing novel pain management therapies. The company is dedicated to addressing unmet medical needs and enhancing patient outcomes by providing innovative, safe, and effective pain relief solutions. Virpax Pharmaceuticals employs advanced technologies and methodologies to develop and optimize its proprietary drug candidates. The company's goal is to provide patients with non-addictive alternatives to traditional pain management methods, ultimately improving their quality of life.


   Company Address: 1055 Westlakes Drive Berwyn 19312 PA
   Company Phone Number: 727-4597   Stock Exchange / Ticker: NASDAQ VRPX
   VRPX is expected to report next financial results on March 21, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Virpax Pharmaceuticals Inc

Major Pharmaceutical Preparations Company Reports Significant Progress as Operating Loss Reaches $-7.7 Million in Q3 2023



The pharmaceutical industry has always been a dynamic and competitive sector, and the Major Pharmaceutical Preparations sector is no exception. Within this environment, Virpax Pharmaceuticals Inc (VRPX) has recently reported its earnings for the period between July and September 30, 2023, revealing a concerning operating loss of $-6.115138 million. While there are signs of improvement when compared to the previous year, with a decrease in losses, the company still faces significant obstacles on its journey towards industry dominance. Moreover, the recent decline in VRPX's stock price adds to the mounting bearish sentiment surrounding the company.
Operating Losses and Inefficiencies:
VRPX's quarterly report for the most recent fiscal period exposes its struggle to operate profitably. With an operating loss of $-6.115138 million, the company has failed to efficiently manage its expenses and generate consistent revenue streams. Although there is a modest improvement compared to the operating loss of $-7.715142 million in the same three-month period the previous year, the continued losses are alarming.

Virpax Pharmaceuticals Inc

Virpax Pharmaceuticals Inc Surges Ahead with Impressive Second Quarter Performance, Trimming Operating Deficit and Shining Despite Lack of Revenue

The stock market is abuzz with anticipation as advisors in the Major Pharmaceutical Preparations sector analyze the second quarter of 2023 earnings. One particular company, Virpax Pharmaceuticals Inc (VRPX), has caught the attention of experts due to its impressive performance.
In their financial reporting period from April to June 30, 2023, VRPX reported an operating deficit of $-3.239487 million. While this may initially seem concerning, it is crucial to highlight that the company has not yet mentioned any revenue. Despite this, VRPX has shown significant improvements compared to the same period in the previous year, where they faced an operating deficit of $-5.904089 million.
This positive trend suggests that VRPX has been operating more efficiently and effectively, even without substantial revenue sources at this time. It is commendable to see a rising business like VRPX manage to trim the diminishing returns in the fiscal period closing June 30, 2023, to $-3.113 million. This marks a significant improvement from the $-5.885 million deficit in the second quarter of 2022.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com